AINDEX
Markets

Spero Therapeutics, Inc. (SPRO)

SPRONASDAQ-GSBiotechnology: Pharmaceutical Preparations

$0.9300

-0.0863 (-8.49%) today

Closed, Nov 16, 4:00 PM ET

-8.49% 1D
Market cap
$58.26m
P/E
11.6
EPS, last 4 quarters
$0.0800
Dividend yield
–
Day range
–
52-week range
$0.9521 to $3.08
Average volume
–
Previous close
$1.02

Analysts

1 covering

Buy1 buy, 0 hold, 0 sell

Targets a year out average $6.00, +545.2% from here

$6.00now $0.9300$6.00

Earnings

next estimate $-0.1400

Next report

Dec 2025

–

Mar 2026

–

Jun 2026

–

Sep 2026

-14.3%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$41.30m$258.0k––
Gross profit$41.30m$258.0k––
Operating income$31.41m-$7.54m-$9.93m-$41.91m
Net income$31.52m-$7.20m-$9.55m-$44.28m

News

8 latest

The company

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company's lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immune-mediated diseases.

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ-GS
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.

Spero Therapeutics, Inc. (SPRO) price, chart and news · AINDEX